AI + Thermal Imaging

Diabetic Foot Ulcer Early Detection and Prevention

DiabSense pairs thermal and visual imaging with AI to help clinicians and high-risk patients detect hotspots, asymmetries, and other risk markers linked to ulcers and complications — non-invasively and fast.

Request early access See devices
Note: This is a pre-commercial product. Not for diagnostic use. Pilot programs forthcoming.

The need

Diabetic Ulceration

Diabetic foot ulcers are extremely expensive, life-threatning event in deep diabetic patients. Ulceration is hard to detect beforehand, and takes a long time to cure with high blood glucose levels and lower blood circulation, commonly found in Diabetic patients

Early Detection - What's Missing

  • Correct tools for daily feet scan for inflamation
  • Deep analysis of circulation issues at clinics
  • Constant remote access to high-risk patients at home

Solution

Full Feet Scan at Home

Daily feet scan at home to detect inflamation early and prevent ulceration

Feet Characterization at Clinic

Deep analysis of diabetic patient feet to detect blood circulation issues early on

Wound Characterization and Monitoring

Continuous monitoring and characterization of wound in order to keep track of wound progress and current condition

How DiabSense works overview

Products

FootScan Pro clinical scanner

FootScan Pro Clinic

Our clinical device for outpatient and wound-care settings. Designed for workflow speed, repeatability, and secure reporting.

  • Dual imaging (thermal + RGB), fixed geometry
  • Automated alignment & AI-assisted analysis
  • Report export & secure sharing
FootScan Home device in hand

FootScan Home At-home

An easy-to-use home device to help high-risk patients track changes between visits and escalate when needed.

  • Guided capture with on-device checks
  • Trend views & clinician-shareable reports
  • Lightweight, compact design

Team & Expertise

Kosala headshot

Kosala

Founder / CEO

20+ years in product development and business management.

Thusitha headshot

Thusitha

CTO

16 years of expertise in electronic product development.

Tharini headshot

Tharini

Business Development Lead

5 years in business management and partnerships.

Gaweshika headshot

Gaweshika

Project Management

Engineering background; 3 years of medical product PM experience.

Ravini headshot

Ravini

Clinical Manager

Biomedical analysis and clinical program management.

Pathum headshot

Pathum

Hardware Dev. Lead
Maleesha headshot

Maleesha

Software Dev. Lead
Shakila headshot

Shakila

QA and Regulation

Consultants & Medical Advisors

Professor Shervanithi headshot

Prof. Shervanithi

Lead Medical Officer

Esteemed vascular surgeon; professor at Leeds and UCL (UK).

Dr. Thushan headshot

Dr. Thushan

Medical Officer

Leads local clinical trials; Sri Lankan medical advisor.

ExcelTech OÜ logo

ExcelTech OÜ

Engineering Partner

Electronics, firmware, cloud, apps, testing, and certification.

Tehnopol logo

Tehnopol

Business Consultancy

Leading Startup Hub in Estonia.

Launch timeline

Concept and Business Analysis
2024 — completed
Early Prototyping
2025 Q1–Q2 — completed
Pre-Clinical Testing
2025 Q1–Q4 — on-going
Advanced Prototype & Comprehensive Pre-Clinical Validation
2025 Q3–Q4 — on-going
Full Product Development
2025 Q2 to 2026 Q2 — on-going
Clinical Trials
Target: 2026 Q3 to 2027 Q1
Product Certification and FDA Application / Approval
Target: 2026 Q3 to 2027 Q1
Pilot Launch (Sampling and Mini bulks)
Target: 2027 Q3 to 2028 Q2
Bulk Launch Start (Singapore + UAE)
Target: 2028 Q4
Continuous Expansion to Multiple Countries
Starting from 2029

Announcements

Announcement 1
Health Founders — Pre‑accelerator Batch 7
Announcement 2
Venture Engine Pitch Competition - Finalists
Announcement 3
DiabSense Finished FootScan Pro V2 Prototype and Started Continuous Pre-Clinical Trials

Investment Opportunity

We are offering investment opportunity for interested investors at ARR above 30%.

  • TAM: 45 Billion USD. SAM: 4 Billion USD. SOM: 220Million USD in 5 years
  • Annual Rate of Return for Investment: >30%
  • Income model: 80% long term subscription income, 20% point of sales income
  • Exit Plans:
    • Plan 1: Aquicition by a big MedTech brand in 2030 (Highly probable)
    • Plan 2: IPO by 2033 (2nd option)
Email us
TAM / SAM / SOM overview

Upcoming Events

VentureEngine pitch competition Final Round
Sep 2025 · Colombo

VentureEngine Pitch Competition — Final Round

We are pitching in VentureEngine pitch competition on 17th September (Final Round).

MEDICA & productronica Germany
Nov 2025 · Germany

MEDICA & productronica

We are participating in Medica and Productronica in Germany in Nov. 2025.

AsiaBerlin Startup Conference
Nov 2025 · Berlin

AsiaBerlin Startup Conference

We are participating in AsiaBerlin startup conference in Nov. 2025.

(Last updated on 14th Sep.)

Contact us

Use the form below or email [email protected]. No data is stored on this site; your email client will open to send your message.

Email directly